⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11729609 | 0.71 | — | — | |
| SCHEMBL3396432 | 0.71 | — | — | |
| SCHEMBL1586291 | 0.62 | — | — | |
| SCHEMBL410315 | 0.56 | — | — | |
| SCHEMBL8690407 | 0.55 | — | — | |
| SCHEMBL77169 | 0.55 | KDM4E (0.37) | — | |
| SCHEMBL77010 | 0.53 | IDO1 (0.35) | — | |
| SCHEMBL26826367 | 0.48 | IDO1 (0.32) | — | |
| SCHEMBL862543 | 0.47 | IDO1 (0.31) | — | |
| Hexamethylbenzene SCHEMBL114857 | 0.45 | RXFP1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046147-B1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2013-05-01 | — | — | EP | disclosed |
| US-7652063-B2 | For therapy of asthma, dysmenorrhea, osteoporosis, bone disorders, constipation, renal disorders, sexual dysfunction, baldness, acute hepatitis, bronchitis, burn, chronic obstructive respiratory diseases, Crohn's disease, digestive ulcer, hemophagous syndrome, hepatopathy, hypercytokinemia at dialysis | ALLERGAN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090311403-A1 | Method of Using Organic Compounds | GIVAUDAN SA (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-2046147-A1 | METHOD OF USING ORGANIC COMPOUNDS | Givaudan SA (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008011742-A1 | METHOD OF USING ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-7169807-B2 | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists | ALLERGAN, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070010495-A1 | 10-HYDROXY-11-DIHYDROPROSTAGLANDIN ANALOGS AS SELECTIVE EP4 AGONISTS | ALLERGAN, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| WO-2005100339-A1 | 10-HYDROXY-11-DIHYDROPROSTAGLANDIN ANALOGS AS SELECTIVE EP4 AGONISTS | ALLERGAN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050228185-A1 | For therapy of asthma, dysmenorrhea, osteoporosis, bone disorders, constipation, renal disorders, sexual dysfunction, baldness, acute hepatitis, bronchitis, burn, chronic obstructive respiratory diseases, Crohn's disease, digestive ulcer, hemophagous syndrome, hepatopathy, hypercytokinemia at dialysis | ALLERGAN, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20040138350-A1 | Stabilized metallocene polyolefins | BASF AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | US | disclosed |